Mirae Asset Global Investments Co. Ltd. Makes New Investment in Eli Lilly and Company $LLY

Key Points

• Mirae Asset Global Investments initiated a sizable Eli Lilly position, purchasing 316,678 shares worth approximately $366.4 million in the third quarter. The stock now represents about 0.6% of its portfolio, while institutional investors collectively own 82.53% of Lilly.
• Eli Lilly reported a strong quarter, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, well above expectations. Robust demand for Mounjaro and Zepbound supported higher guidance and prompted several analysts to raise price targets.
• Despite strong momentum, investors face risks from Lilly’s premium valuation, heavy reliance on GLP-1 drugs, potential pricing pressure from Medicare programs, and signs that growth could moderate. The stock trades near its 52-week high at a market value of roughly $1.33 trillion.

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 316,678 shares of the company's stock, valued at approximately $366,422,000. Eli Lilly and Company makes up about 0.6% of Mirae Asset Global Investments Co. Ltd.'s investment portfolio, making the stock its 21st biggest position.

Several other large investors also recently bought and sold shares of LLY. ARQ Wealth Advisors LLC raised its stake in Eli Lilly and Company by 6.5% in the third quarter. ARQ Wealth Advisors LLC now owns 571 shares of the company's stock valued at $661,000 after buying an additional 35 shares in the last quarter. Stevens Capital Partners lifted its stake in Eli Lilly and Company by 33.3% in the third quarter. Stevens Capital Partners now owns 668 shares of the company's stock valued at $773,000 after buying an additional 167 shares during the last quarter. Profund Advisors LLC boosted its stake in Eli Lilly and Company by 11.6% during the 3rd quarter. Profund Advisors LLC now owns 10,648 shares of the company's stock worth $12,321,000 after purchasing an additional 1,110 shares during the period. ProShare Advisors LLC boosted its stake in shares of Eli Lilly and Company by 4.0% during the third quarter. ProShare Advisors LLC now owns 134,385 shares of the company's stock worth $155,494,000 after buying an additional 5,181 shares during the period. Finally, Vise Technologies Inc. lifted its position in Eli Lilly and Company by 19.9% during the 3rd quarter. Vise Technologies Inc. now owns 41,180 shares of the company's stock worth $47,648,000 after acquiring an additional 6,827 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an "overweight" rating in a report on Monday. Guggenheim increased their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. Royal Bank Of Canada lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an "outperform" rating in a research report on Friday. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an "overweight" rating in a research note on Friday. Finally, Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an "overweight" rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,404.14.

Eli Lilly and Company Trading Down 0.4%

NYSE:LLY opened at $1,412.06 on Tuesday. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,449.68. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a fifty day simple moving average of $1,200.81 and a 200-day simple moving average of $1,094.25. The company has a market capitalization of $1.33 trillion, a PE ratio of 45.83, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm's revenue was up 38.6% on a year-over-year basis. During the same period in the prior year, the company earned $7.02 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company's payout ratio is presently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 over the last quarter. Corporate insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.